Methylene Blue for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Methylene Blue for Health & Longevity

Created on 07/07/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A 150-year-old synthetic dye and hospital antidote now explored for energy and healthy aging. Its strongest human evidence lies in emergency and surgical care; everyday brain and skin benefits for healthy adults stay unproven. A single low morning dose may briefly sharpen attention, but mixing it with serotonin-raising products can be life-threatening. (Full Review)

Protocol

Dose
5–15 mg
often 0.5–4 mg/kg; low "less is more" window
Timing
Morning
daytime cognitive effects; avoids sleep disruption
Frequency
Once daily
single low oral dose; splitting not needed
Time to effect
Methemoglobinemia reversal
30–60 min
after a single low intravenous dose
Acute cognitive effects
~1 hour
after a low oral dose; fade over hours

Benefits

Contraindications
  • Serotonergic prescription drugs (SSRIs, SNRIs, MAOIs, tricyclics)
  • G6PD deficiency
  • Pregnancy or breastfeeding
  • Severe kidney impairment (eGFR <30 mL/min/1.73m²)
  • Infants under 3 months
    •
Key Interactions
  • OTC serotonergic agents (dextromethorphan, triptans, tramadol, St. John's Wort)
  • Serotonergic supplements (5-HTP, L-Tryptophan, SAMe)
  • High-dose vitamin C in G6PD deficiency
  • Nitric-oxide-lowering or other MAO-inhibiting substances
  • Methemoglobinemia-causing drugs (dapsone, benzocaine, nitrates)
    •

Risk & Side Effects

  • High: Serotonin syndrome; methemoglobinemia & hemolytic anemia at high doses / G6PD deficiency; benign discoloration of urine, skin, sclera, and oral mucosa
    •
  • Medium: Gastrointestinal effects; genitourinary symptoms
    •
  • Low: Cardiovascular effects; interference with pulse oximetry and laboratory readings
    •
  • Speculative: Unknown long-term safety of chronic low-dose use; pro-oxidant harm at supraphysiologic doses
    •

Monitoring

Marker Target Why
G6PD activity Normal enzyme activity Deficiency makes the drug cause red-cell destruction
Methemoglobin <1% of total hemoglobin Detects the paradoxical high-dose blood effect
Hemoglobin / CBC ~13.5–15 g/dL Screens for anemia and hemolysis
eGFR >90 mL/min/1.73m² Kidney clearance governs elimination

Cadence: Baseline panel, then a check at ~4–8 weeks if used regularly, and every 6–12 months thereafter

Qualitative Assessment

  • Subjective attention, mental clarity, and word recall in the hours after a morning dose
  • Daytime energy and stamina
  • Mood and stress resilience
  • Absence of adverse signals (agitation, tremor, sweating, racing heart, breathlessness)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.